Loading clinical trials...
Loading clinical trials...
A PHASE 2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH BRCA OR ATM MUTANT TUMORS JAVELIN BRCA/ATM
Conditions
Interventions
Avelumab
Talazoparib
Locations
100
United States
Stanford Cancer Center
Palo Alto, California, United States
Stanford Women's Cancer Center
Palo Alto, California, United States
Stanford Healthcare
Stanford, California, United States
Stanford University School of Medicine
Stanford, California, United States
Atlanta Cancer Care -Alpharetta
Alpharetta, Georgia, United States
Northside Hospital, Inc. - GCS/Athens
Athens, Georgia, United States
Start Date
June 18, 2018
Primary Completion Date
March 28, 2022
Completion Date
February 3, 2023
Last Updated
September 25, 2023
NCT06307795
NCT06716138
NCT05581004
NCT06974812
NCT06107686
NCT05205109
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions